Industry Picks Holes In UK Plans For Post-Brexit Drug Regulation
Plans for a post-Brexit standalone regulatory system have drawn a mixed response from UK pharmaceutical industry bodies, which are worried about aspects of proposals on future drug approval routes, orphan and pediatric drug incentive schemes, and the “grandfathering” of existing EU marketing authorizations. They are also calling for financial compensation should the UK not be part of Europe's the new drug verification system.
You may also be interested in...
A recent debate in the House of Lords saw some fiery words exchanged over the government’s plans for the life science sector in the event of a no-deal Brexit, with accusations that they would produce a “clunky” regulatory system and put industry’s future “at grave risk.”
The UK MHRA has updated its guidance on how it plans to regulate medicines and healthcare products if the UK leaves the EU without a deal. Among many other things, it includes the promise of free scientific advice for SMEs and details on how marketing applications for centrally authorized products will be converted into UK ones in the event of a hard Brexit.
A new leader is needed for MHRA as UK agency CEO Ian Hudson announces he'll leave next September. Someone else will have to reshape and guide the agency after Brexit.